Skip to main content
OpenTrials
Completed

NCT Number: NCT03561181

Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

The purpose of this study is to evaluate safety of S.flexneriza-S.sonnei Bivalent Conjugate Vaccine in healthy volunteers aged above 3 Months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 month and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Yizhou Center for Disease Control and Prevention

Yizhou, Guangxi, 546300, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 3 months old and above healthy people.
  • Subject or legal representative who consent and has signed written informed consent.
  • Subject and parent/guardian who is able to comply with all study procedures.
  • Subject who did't receive blood products within 30 days ,immune with any live vaccine within 14 days and inactivated vaccine within 7 days before vaccination.
  • Axillary temperature ≤37.0 ℃.

Exclusion criteria

  • Febrile illness (temperature ≥ 38°C) in the 3 days.
  • Subject who are allergic to tetanus toxoid.
  • Allergic history after vaccination.
  • Immunodeficiency diseases patients who administered with immunosuppressive agents.
  • In pregnancy or lactation or pregnant women.
  • Subject who are suffering from serious chronic diseases, infectious diseases, active infection, cardiovascular disease,liver or kidney disease.
  • Subject who have symptoms such as diarrhea, abdominal pain, and pus and bloody stools in the past 3 days.
  • History of allergy,eclampsia, epilepsy,brain trauma,encephalopathy and mental disease or family disease.
  • Subject who diagnosis of thrombocytopenia or other history of coagulopathy may cause intramuscular contraindication.
  • Children with abnormal labor(pregnancy week<37w,>42w),birth weight (<2500g,>4000g), asphyxia rescue history,congenital malformations or developmental disorders(Only applicable to 3-5 months old group)
  • Blood routine, blood chemistry and urinalysis laboratory collection abnormalities and the severity of grade 2 and above before immunization.
  • Subject who plan to participate in or is in any other drug clinical trial.
  • Any condition that, in the judgment of investigator, may affect trial assessment.

Treatment and study plan

S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine

Biological

Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

Primary outcomes

  1. Occurrence of adverse events during a 30 day follow-up period after each vaccination

    Time frame: 30 day after each vaccination

Sponsors and collaborators

Lead sponsor

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Industry

Registry information

Official study title

A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jun 19, 2018
Registry last updated
Oct 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.